Pharma Focus Asia

CENTOGENE Extends Strategic Partnership with Takeda

Tuesday, April 11, 2023

CENTOGENE announced it has extended its partnership with Takeda to diagnose patients with Lysosomal Storage Disorders (LSDs).

Under the renewed one-year partnership agreement, CENTOGENE will continue to provide Takeda with access to diagnostic testing for patients around the world. The aim of the commercial fee-for-service agreement is to enhance patient access to rapid and reliable diagnostics for LSDs, including Fabry disease, Gaucher disease, and Hunter syndrome.

This expanded partnership with Takeda accelerates diagnosis and increase access to life-saving therapeutics for patients globally. This collaboration continues to play a vital role in the expansion of Takeda’s world-class enzyme replacement treatments and most importantly, brings life-changing answers to underserved patient communities.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Thermo Fisher Scientific - Rapid Mycoplasma TestingAsia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024ISPE Singapore Affiliate Conference & Exhibition 2024